What's more, there was a correlation between the severity of psoriasis and high blood pressure.

According to the NHS, in severe cases of psoriasis, the skin around your joints may crack and bleed.

"Treatments are determined by the type and severity of your psoriasis, and the area of skin affected," explains the health body.

It adds: "Your doctor will probably start with a mild treatment, such as topical creams applied to the skin, and then move on to stronger treatments if necessary."

If your psoriasis is linked to high blood pressure, you should overhaul aspects of your lifestyle to lower you reading.

Improving your diet is integral to this effort and one of the quickest and most effective countermeasures is to cut back on salt.

According to Action on Salt, a research outfit based at Queen Mary University of London, a high salt diet disrupts the natural sodium balance in the body.

"This causes the body to retain water, which increases the pressure of the pushing of blood against the vessel walls," warns the health body.

"As a nation, if we can cut one gram of salt from our average daily salt intake, there would be approximately 6,000 fewer deaths from strokes and heart attacks each year in the UK," it says.

According to the NHS, eating a low-fat diet that includes lots of fibre, such as wholegrain rice, bread and pasta, and plenty of fruit and vegetables also helps lower blood pressure.

"Being active and taking regular exercise lowers blood pressure by keeping your heart and blood vessels in good condition," notes the health body.

Adults should do at least 150 minutes (two hours and 30 minutes) of moderate-intensity aerobic activity, such as cycling or fast walking, every week, it adds.

Read more from the original source:

High blood pressure warning - the change on your skin that could signal you're at risk - Express

SIMPONI ARIA (golimumab) is a fully human monoclonal antibody used for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA). Credit: Janssen Biotech, Inc. The 4ml single-use vial of SIMPONI ARIA contains 50mg of golimumab. Credit: A2-33. SIMPONI ARIA acts as a tumor necrosis factor (TNF)-blocker.

SIMPONI ARIA (golimumab) is a fully human anti-tumour necrosis factor (TNF) alpha monoclonal antibody.

It is indicated for the treatment of moderate-to-severe active rheumatoid arthritis (RA) and active ankylosing spondylitis (AS) in adult patients, as well as active polyarticular juvenile idiopathic arthritis (pJIA) and active psoriatic arthritis (PsA) in patients aged two years and older.

SIMPONI ARIA is available in a single-use vial as a colourless to a light-yellow solution in 50mg / 4ml (12.5mg / ml) dosage strength for intravenous administration.

Discovered and developed by Janssen Biotech, golimumab was initially approved as a subcutaneous injection under the trade name Simponi by the US Food and Drug Administration (FDA) for the treatment of RA, PsA and AS in adult patients in 2009.

SIMPONI was approved in Europe for the treatment of moderate-to-severe RA, active and progressive PsA, severe, active AS, active ulcerative colitis, severe active non-radiographic axial spondyloarthritis and pJIA.

In July 2013, the intravenous form of golimumab obtained FDA approval under the trade name Simponi Aria for the treatment of moderate-to-severe active RA in combination with methotrexate (MTX).

The company submitted two supplemental biologics license applications (sBLAs) for Simponi Aria to the FDA for the treatment of PsA and AS in adult patients in December 2016. The applications were approved in October 2017.

The FDA also received two sBLAs for Simponi Aria for the treatment of active pJIA and PsA in paediatric patients in April 2020. The drug was approved for the indications in September 2020.

SIMPONI ARIA is marketed in 24 countries for one or more of the aforementioned indications.

Juvenile idiopathic arthritis (JIA), previously known as juvenile rheumatoid arthritis, is an arthritis-like inflammatory condition in children characterised by joint swelling, stiffness and pain, persistent for at least six weeks.

The polyarticular form of JIA is most common and is characterised by inflammation in more than four joints, closely resembling adult RA.

PsA is a chronic inflammatory disease characterised by both joint inflammation and skin lesions associated with psoriasis. PsA in paediatric patients is one of the rarest forms of JIA, observed in 2% to 11% of JIA patients.

Other characteristics of psoriatic arthritis include finger and nail defects or complications with the eye.

Golimumab is an anti-TNF biologic agent that binds to soluble and transmembrane bioactive forms of human TNF-alpha, a cytokine protein whose overproduction in the body leads to several chronic inflammatory diseases.

Inhibition of the interaction of TNF-alpha to its receptors inhibits its biological activity.

FDA approval of SIMPONI ARIA for pJIA is based on results from the open-label, multi-centre, phase three clinical trial, GO-VIVA.

SIMPONI ARIA is available in a single-use vial as a colourless to a light-yellow solution in 50mg / 4ml (12.5mg / ml) dosage strength for intravenous administration.

The trial evaluated the safety and efficacy of SIMPONI ARIA in 127 patients with pJIA aged two years to 17 years, following MTX treatment for at least two months.

The efficacy of the drug was consistent with responses in adult patients with RA through 52 weeks.

SIMPONI ARIAs pharmacokinetic (PK) exposure was consistent with the two pivotal phase three clinical trials in adult patients with moderate-to-severe active RA and active PsA.

The safety profile established for SIMPONI ARIA in paediatric patients was also consistent with the results in adult RA and PsA patients.

Common side-effects of SIMPONI ARIA reported in patients during the clinical trial are viral infections, upper respiratory tract infection, increased levels of alanine aminotransferase and aspartate aminotransferase, decreased neutrophil count, rash, bronchitis and high blood pressure.

Read more from the original source:

SIMPONI ARIA (golimumab) for the Treatment of pJIA - Clinical Trials Arena

Interim data expected by mid-2021

CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it has dosed the first patients in its Phase 2 clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis. EDP1815 is an investigational oral biologic in development for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19.

We are pleased to announce the dosing of the first patients in our Phase 2 clinical trial in mild to moderate psoriasis, said Duncan McHale, M.B.B.S., Ph.D., Chief Medical Officer of Evelo. In Phase 1b studies, EDP1815 demonstrated an ability to resolve systemic inflammation and provide clinical benefit to patients with psoriasis. Based on these data, EDP1815 may offer an improved profile to existing products and others in development. EDP1815 has the potential to be an effective, well-tolerated, and convenient medicine for millions of patients with mild to moderate psoriasis. Our Phase 2 trial, if successful, will enable us to advance into confirmatory registrational studies, following meetings with health authorities such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). We look forward to interim data by mid-2021, as we continue to progress this important therapy toward market.

EDP1815-201 is a double-blind, placebo-controlled, dose-ranging Phase 2 trial designed to evaluate three doses of the enteric capsule formulation of EDP1815 versus placebo in 225 patients with mild to moderate psoriasis over a 16-week treatment period. The primary endpoint is mean reduction in Psoriasis Area and Severity Index (PASI) score at 16 weeks. Key secondary endpoints include other clinical measures of disease such as Physicians Global Assessment (PGA), Body Surface Area (BSA), PGA x BSA, Psoriasis Symptom Inventory (PSI), Dermatology Life Quality Index (DLQI), and Lesion Severity Score (LSS). Interim data from the study is expected by mid-2021.

About EDP1815 in Psoriasis EDP1815 is an investigational oral biologic being developed for the treatment of inflammatory diseases.EDP1815 is a strain ofPrevotella histicola, selected for its specific pharmacology. In thesecondandthirdquarter of 2019, Evelo reported positive Phase 1b interim clinical data in two cohorts of patients with mild to moderate psoriasis. EDP1815 was well tolerated at both doses, with no overall difference reported from placebo. There was a reduction in mean LSS and PASI score after 28 days of dosing in both cohorts who received EDP1815. In the high dose cohort alone, there was a continued reduction in both mean LSS (of 24% vs. placebo of 7%) and PASI score (of 21% vs. placebo of 3%) at 42 days 14 days following the last dose of the drug. This may indicate a sustained clinical effect and dose response. EPD1815 was also observed to limit the systemic production of multiple inflammatory cytokines, including IL-6, IL-8, TNF, and IL-1, which are well-established mediators of potentially harmful effects in patients with inflammatory diseases.

About PsoriasisPsoriasis is a common chronic immune-mediated inflammatory skin disease, affecting up to 3% of the population worldwide. The disease is driven by Th17-inflammation, which results in the formation of thickened red plaques with scaling. Psoriatic lesions can appear anywhere on the body but are most often seen on the knees, elbows, scalp, and lumbar area. There is a strong association with psoriatic arthritis, depression, and metabolic syndrome.

Patients with mild to moderate psoriasis are underserved by current treatments, including topical therapies, which do not control systemic inflammation, have low rates of compliance, or in the case of potent topical steroids, are not recommended for long-term use. The majority of novel therapies, including injectable high-cost biologics, are only approved for patients with moderate to severe disease. Even in this patient population, the majority of eligible patients do not receive biologics, instead opting for topical or oral systemic therapies, which are associated with tolerability issues and/or with monitoring requirements tied to safety concerns.

About Evelo BiosciencesEvelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The companys first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelos therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit http://www.evelobio.com and engage with Evelo on LinkedIn.

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements concerning the timing and results of any clinical trials or readouts for EDP1815, our development plans, and the promise and potential impact of EDP1815 or our other product candidates.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our operations, including our preclinical studies and clinical trials, and the continuity of our business; we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our unproven approach to therapeutic intervention; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in regulatory approval; our reliance on third parties and collaborators to expand our microbial library, conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; our lack of experience in manufacturing, selling, marketing, and distributing our product candidates; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; risks associated with international operations; our ability to retain key personnel and to manage our growth; the potential volatility of our common stock; our management and principal stockholders have the ability to control or significantly influence our business; costs and resources of operating as a public company; unfavorable or no analyst research or reports; and securities class action litigation against us.

These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

ContactJessica Cotrone, 978-760-5622jcotrone@evelobio.com

Here is the original post:

Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis - GlobeNewswire

Chronic Plaque Psoriasis Therapeutics Market Report Delivering Growth Analysis with Key Trends of Top Companies (2020-2026)

A comprehensive research study on the Chronic Plaque Psoriasis Therapeutics Marketwas recently published by Market Report Expert. This is an up-to-date report, covering the current COVID-19 impact on the market. The Coronavirus (COVID-19) has affected every aspect of life globally and thus altering the global market scenario. The changes in the market conditions are drastic. The swiftly changing market scenario and initial and future assessment of the impact on Chronic Plaque Psoriasis Therapeutics market is covered in the report.The Chronic Plaque Psoriasis Therapeutics Market report is a precise and deep-dive study on the current state that aims at the major drivers, market strategies, and imposing growth of the key players. Worldwide Chronic Plaque Psoriasis Therapeutics Industry also offers a granular study of the dynamics, segmentation, revenue, share forecasts, and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Chronic Plaque Psoriasis Therapeutics industry.

The Global Chronic Plaque Psoriasis Therapeutics Market poised to grow from US$ XX million in 2020 to US$ XX million by 2026 at a compound annual growth rate (CAGR) of XX% during the projection period of 2020-2026.

An Outline of the Major Key Players covered in this Report:

Abbvie, Novartis International, Pfizer, Merck, Astelllas Pharma, GlaxoSmithKline

Get Free LatestPDF Template of this Report(Including Covid-19 impact analysis on overall industry Forecast, Size, Share, CAGR and more.)@ https://www.marketreportexpert.com/report/Chronic_Plaque_Psoriasis_Therapeutics_/16952/sample

Note: We can also provide market report in German/French Language.

The report puts together a succinct analysis of the growth drivers influencing the current business scenario across various regions and countries. Substantial information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present a collaborative prediction. Additionally, this report encompasses a precise competitive analysis of major market players, innovative companies, and their strategies during the projection timeline.

The latest report on the Chronic Plaque Psoriasis Therapeutics Market consists of an analysis of this industry and its type, application, and other segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period of 2020-2026.

Majortype, primarily split into

ClinicalNon-ClinicalInactive

Major applications/end users, including

HospitalsAmbulatory Surgical CentersOthers

According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.

Feel Free! Ask Our Industry Expert For Discount on this Report(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends. Also we are offering 20% discount.): https://www.marketreportexpert.com/report/Chronic_Plaque_Psoriasis_Therapeutics_/16952/inquiry

The research offers an analysis of the geographical landscape of the Chronic Plaque Psoriasis Therapeutics Market, which is divided into regions such as North America, Europe, Asia Pacific, South America, and the Middle East & Africa. The segment includes data about several parameters related to the regional contribution such as market share, application share, type share, key companies in respective regions, market share of key companies in regional market, growth rate and revenue of the regional market, sales, production, and consumption of the respective Chronic Plaque Psoriasis Therapeutics market.

Major Highlights of TOC Covers:

Chronic Plaque Psoriasis Therapeutics Market 2020, Chronic Plaque Psoriasis Therapeutics Market size, Chronic Plaque Psoriasis Therapeutics Market share, Chronic Plaque Psoriasis Therapeutics Market analysis, Chronic Plaque Psoriasis Therapeutics Market forecast, Chronic Plaque Psoriasis Therapeutics Market trends, Chronic Plaque Psoriasis Therapeutics Market Research report, Chronic Plaque Psoriasis Therapeutics application, Chronic Plaque Psoriasis Therapeutics Trends, Chronic Plaque Psoriasis Therapeutics Market growing CAGR, Chronic Plaque Psoriasis Therapeutics Market Competitive Landscape, Chronic Plaque Psoriasis Therapeutics Market Growth

Information related to the growth rate, revenue, sales, production, consumption, during the forecast period is included in the report. The Chronic Plaque Psoriasis Therapeutics Market report claims that the industry is projected to generate significant revenue and sales during the forecast period. The report consists of information related to the market dynamics such as challenges involved in this vertical, growth opportunities, and driving factors affecting the market.

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email inquiry@marketreportexpert.comWeb:-https://www.marketreportexpert.com

Continue reading here:

COVID-19 Impact on Chronic Plaque Psoriasis Therapeutics Market New Trends, Size, Share, Growth, Outlook, Overview, Application and Forecast 2020 to...

Oct. 13, 2020 11:00 UTC

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it will host a conference call with investors to provide an update on its Phase III psoriasis study and the positive interim data analysis and recommendations from the studys Independent Data Monitoring Committee (IDMC). Dr. Michael Goldfarb, M.D., Dermatologist, Beaumont Hospital, Dearborn, Michigan, U.S., a key opinion leader in the treatment of psoriasis, will join the call which is scheduled to take place on Thursday, October 15, 2020 at 4:15 pm EDT.

Piclidenoson, Can-Fites lead drug candidate, offers several potential key benefits over psoriasis treatments currently on the market. As an oral pill taken twice daily, it offers ease of administration for patients who tend to prefer oral medications over injectables. As an oral drug, the Company believes Piclidenoson may be priced at a significantly lower cost than injectable biologics, and somewhat lower than the current oral medication on the market, Otezla. A 2018 study on psoriasis patient preferences published in American Health & Drug Benefits showed the two most important considerations for choosing a psoriasis drug were route of administration and cost, with oral administration and lower cost being most preferred.

Piclidenoson has been dosed in over 1,500 patients with an excellent safety profile in clinical trials to date. In contrast, the biologics on the market approved to treat psoriasis have black box warnings. While psoriasis is a serious disease with quality of life implications for patients, it is not life threatening and therefore patients recognize that while they need a treatment that is effective, safety is also a very high priority.

With an estimated 125 million cases worldwide, psoriasis is considered an immune system problem that causes infections, stress and is a chronic disease with no cure. The market size for psoriasis is estimated to be $11.5 billion at the end of 2020.

The call will take place on Thursday, October 15th 2020 at 4:15 pm EDT. Investors in the U.S. are invited to dial 1-877-423-9813. International investors may dial 1-201-689-8573. The conference ID is 13711928.

Investors may also participate via webcast: http://public.viavid.com/index.php?id=141970

A replay of the webcast will be archived on Can-Fites website for a period of time.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for rheumatoid arthritis/psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: http://www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fites expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as believe, expect, intend, plan, may, should or anticipate or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fites authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fites actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fites actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the recent outbreak of coronavirus; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fites filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005454/en/

Read the original:

Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020 - BioSpace

Secukinumab may be a safe and effective treatment for patients with psoriatic disease, comorbidities, and treatment failure, according to results of a retrospective study published in Dermatologic Therapy. The fully human IgG1/k monoclonal antibody has been shown to be safe and effective in the treatment of psoriasis in phase 3 trials, but has not yet been tested in the general population.

To determine the clinical effectiveness and safety of secukinumab in a real-life cohort of patients with moderate to severe psoriasis vulgaris, data from 120 patients (35.8% women) were analyzed. The mean age of participants was 49.813.5 years and 65% of participants were diagnosed with additional forms of psoriasis. The extent and severity of psoriasis was measured using the Psoriasis Area Severity Index (PASI).

After 3 months of secukinumab therapy, the mean PASI of the entire population was significantly lower than baseline (P <.001) and was maintained at 12 month follow-up (P <.001). Total clearance (PASI 0) was achieved after 12 months in 46% of those with psoriatic onychopathy (1 of the more difficult forms of psoriasis to treat), 75% of patients with moderate to severe scalp psoriasis, 57% of patients with psoriasis of the genital area, and 38% of patients with palmoplantar psoriasis. In all, 28 adverse effects were recorded in the first year of treatment, resulting in 8 patients discontinuing treatment. After 12 months, patients who had been unresponsive to 2 or more lines of biologic agents had a lower rate of treatment persistence (71%) than those who were bio-naive (93%) or had a history of inefficacy to only 1 biologic agent (88%)(P =.009 for trend).

Limitations to this study include its small cohort and retrospective design. Future research with a larger cohort and that investigates the impact of body mass index on therapeutic effectiveness are warranted.

The results of this study indicated to the researchers that secukinumab is effective and safe in the treatment of psoriasis in patients with a range of comorbidities and in areas that are difficult to treat. These results were significant despite a mean persistence to treatment of 85% after 12 months.

Disclosure: Medical writing assistance for this publication was provided by Novartis. Please see the original reference for a full list of authors disclosures.

Reference

Carpentieri A, Mascia P, Fornaro M, et al. Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: A multicenter real-life study. [published online July 18, 2020]. Dermatol Ther. doi:10.1111/dth.14044

Follow this link:

Secukinumab Effective in Real-Life Patients With Moderate-Severe Psoriasis - Dermatology Advisor

A recent Cochrane review suggests very few studies offer sufficient evidence supporting the efficacy and safety of exposure to artificial ultraviolet (UV) B while soaking in an indoor salt bath, an approach termed balneophototherapy, for the treatment of chronic plaque psoriasis. Abridged findings from this review were published in the British Journal of Dermatology.

An international team of researchers reviewed 8 randomized controlled trials consisting of 1976 participants with psoriasis. In 6 trials, different treatments were applied to different participants, whereas 2 other trials examined different treatments applied to the same participant but to different body parts.

Across all studies, the mean age for participants ranged between 41 to 50 years, and the median Psoriasis Area and Severity Index (PASI) score ranged from 15 to 18 across 5 studies. Only 1 trial examined salt baths plus UVB vs other treatments without UVB (ie, psoralen bath plus UVA). Trials spanned from 2 to 13 months in duration.

Several limitations affected the researchers confidence in the evidence of these trials. These limitations included risk for bias, such as in terms of inadequate blinding and high probability of publication bias. The researchers noted that commercial spa or salt companies sponsored 3 studies, health insurance companies sponsored 1 study, a dermatologist association sponsored 1 study, and 3 studies had no reported funding sources.

In addition, reporting of the reviewers specified outcomes including Dermatology Life Quality Index, pruritus severity using a visual analogue scale from 0 (no itching) to 100 (severe itching), time to relapse, and secondary malignancies were either limited or nonexistent.

According to the researchers who conducted this Cochrane review, further randomized controlled trials are needed to evaluate PASI 75 and even PASI 90 or 100, in addition to treatment-related adverse events requiring withdrawal, to gain a deeper understanding of the efficacy and safety of balneophototherapy. To consider any potential harm by UVB exposure, they wrote, future study protocols should include long-term observations.

Dislcosure: Please see the original reference for a full list of authors disclosures.

Reference

Peinemann F, Harari M, Peternel S, et al. Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis: abridged Cochrane review. Published online July 6, 2020. Br J Dermatol. doi:10.1111/bjd.19385

Originally posted here:

More Long-Term Randomized Trials Are Needed to Support Balneophototherapy for Chronic Psoriasis - Dermatology Advisor

Aim:Although the pathogenic mechanisms of psoriatic arthritis (PsA) are not completely clarified, evidence suggests that interleukin 17A (IL-17A)-mediated immune responses play a pivotal role in the disease. This is best underscored by the important clinical effectiveness of IL-17A inhibitors in psoriasis treatment. We aim to investigate the predictive value of IL-17A in detecting the early axial spondyloarthropic (SpA) changes in psoriatic patients.

Methods:The study enrolled 100 patients with psoriasis, classified into group 1, included 62 patients with only psoriatic skin lesions (Ps), and group 2 included 38 patients with PsA, and 100 age and gender matched healthy volunteers. All participants were subjected to general and local clinical examination, laboratory assessment including IL-17A in the serum by means of enzyme-linked immunosorbent assay, and axial joint radiological assessment.

Results:Our study included 60 males (60%) and 40 females (40%).The positive radiological findings of early axial SpA changes were found among 30.6% of the Ps group and among 84.2% of the PsA group. There were significant differences between patients with positive magnetic resonance imaging (MRI) findings of early axial SpA and patients with negative MRI findings in both groups regarding IL-17A levels. There was a significant association between IL-17A level and early axial SpA changes in psoriatic patients with a clear cutoff point (222.5).

Conclusion:Our study can imply that IL-17A is a valuable, useful and low-cost biomarker in detecting early axial SpA changes in asymptomatic and nonradiographic axial SpA (nr-axial SpA) psoriatic patients that helps early management and prevent progressive axial involvement and disabilities.

Keywords:IL-17A; axial SpA; psoriasis; spondyloarthritic changes.

Continued here:

Interleukin-17A biomarker as a predictor for detection of early axial spondyloarthritis changes in patients with psoriasis - DocWire News

Whether the Simplified Psoriasis Index (SPI), a recently created multidomain instrument for evaluating psoriasis, has utility was ascertained in a study examining response to secukinumab. Patients suffering from moderatetosevere plaque psoriasis were administered secukinumab 300mg subcutaneously once weekly from baseline to W4, then every 4weeks until W48, in an openlabel, multicentre study including 17 French centres. As per findings, reduction of Psoriasis Area and Severity Index (PASI) scores following treatment with secukinumab was shown to be closely correlated with proSPIs (SPI psoriasis severity), supporting the latter's appropriateness for evaluating response to therapy. Despite a slightly weaker correlation between PASI and saSPIs (selfassessed severity), patients were shown to be capable of finishing a valid evaluation of their psoriasis independently, and therefore potentially remotely. With the added advantage of psychosocial impact assessment (SPIp), SPI affords a valid instrument allowing patients to evaluate their own psoriasis, remotely if required.

Excerpt from:

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderatetosevere psoriasis as assessed by the Simplified Psoriasis Index:...

To compare disease characteristics, quality of life (QOL), and work productivity of patients with psoriatic arthritis (PsA) who had multidomain vs single-domain presentations.Adults with PsA enrolled in the Corrona PsA/SpA Registry (March 2013-August 2018) were included. Six PsA disease domains were evaluated: enthesitis, dactylitis, peripheral arthritis (PA), nail psoriasis, axial disease, and skin disease. Patients were classified as having multidomain ( 2 domains) or single-domain disease presentations; biologic initiators were characterized separately. Linear regression models evaluated the association of multidomain presentations with disease characteristics, QOL, and work productivity vs single-domain presentations.Of 2617 patients with PsA, 1698 (64.9%) had multidomain presentations, 617 (23.6%) had single-domain presentations, and 302 (11.5%) had no active disease features. Of 354 biologic initiators, 289 (81.6%) had multidomain presentations, 45 (12.7%) had single-domain presentations, and 20 (5.6%) had no active disease features. Overall, the most common singledomain and multidomain presentations, respectively, were skin disease (12.7%) and PA + skin disease (11.7%). Multidomain presenters were more likely to have fibromyalgia, depression, anxiety, and prior biologic use than single-domain presenters. Multidomain presentations were associated with significantly worse patient and physician global assessments of disease activity, pain, and fatigue; Health Assessment Questionnaire Disability Index and EQ-5D scores; and work productivity at enrollment.In this US real-world cohort, most patients had multidomain disease presentations, which was associated with worse disease activity, QOL, and work productivity measures. This study highlights the heterogeneity of PsA and the importance of assessing all PsA domains for optimizing disease management.

PubMed

Excerpt from:

Impact of Multidomain Disease Presentations on Patients With Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. -...

The global Psoriasis market focuses on encompassing major statistical evidence for the Psoriasis industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Psoriasis study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Psoriasis industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Psoriasis market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Psoriasis report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Psoriasis market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Psoriasis Market report @ https://hongchunresearch.com/request-a-sample/40648

Key players in the global Psoriasis market covered in Chapter 4:Celgene CorporationTakeda Pharmaceutical Company LimitedPfizer Inc.Stiefel Laboratories Inc.Amgen Inc.Biogen IdecNovartis AGEli Lilly and CompanyJohnson and Johnson (Janssen Biotech Inc.)AbbVie Inc.

In Chapter 11 and 13.3, on the basis of types, the Psoriasis market from 2015 to 2026 is primarily split into:SystemicPhototherapyTopical TreatmentOthers

In Chapter 12 and 13.4, on the basis of applications, the Psoriasis market from 2015 to 2026 covers:InjectableTropicalOral

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

The Psoriasis market study further highlights the segmentation of the Psoriasis industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Psoriasis report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Psoriasis market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Psoriasis market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Psoriasis industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Psoriasis Market Report with [emailprotected]https://hongchunresearch.com/report/psoriasis-market-40648

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Psoriasis Market

Chapter Four: Players Profiles

Chapter Five: Global Psoriasis Market Analysis by Regions

Chapter Six: North America Psoriasis Market Analysis by Countries

Chapter Seven: Europe Psoriasis Market Analysis by Countries

Chapter Eight: Asia-Pacific Psoriasis Market Analysis by Countries

Chapter Nine: Middle East and Africa Psoriasis Market Analysis by Countries

Chapter Ten: South America Psoriasis Market Analysis by Countries

Chapter Eleven: Global Psoriasis Market Segment by Types

Chapter Twelve: Global Psoriasis Market Segment by Applications 12.1 Global Psoriasis Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Psoriasis Sales and Market Share by Applications (2015-2020) 12.1.2 Global Psoriasis Revenue and Market Share by Applications (2015-2020) 12.2 Injectable Sales, Revenue and Growth Rate (2015-2020) 12.3 Tropical Sales, Revenue and Growth Rate (2015-2020) 12.4 Oral Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Psoriasis Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/40648

List of tablesList of Tables and Figures Table Global Psoriasis Market Size Growth Rate by Type (2020-2026) Figure Global Psoriasis Market Share by Type in 2019 & 2026 Figure Systemic Features Figure Phototherapy Features Figure Topical Treatment Features Figure Others Features Table Global Psoriasis Market Size Growth by Application (2020-2026) Figure Global Psoriasis Market Share by Application in 2019 & 2026 Figure Injectable Description Figure Tropical Description Figure Oral Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Psoriasis Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Psoriasis Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Psoriasis Figure Production Process of Psoriasis Figure Manufacturing Cost Structure of Psoriasis Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table Celgene Corporation Profile Table Celgene Corporation Production, Value, Price, Gross Margin 2015-2020 Table Takeda Pharmaceutical Company Limited Profile Table Takeda Pharmaceutical Company Limited Production, Value, Price, Gross Margin 2015-2020 Table Pfizer Inc. Profile Table Pfizer Inc. Production, Value, Price, Gross Margin 2015-2020 Table Stiefel Laboratories Inc. Profile Table Stiefel Laboratories Inc. Production, Value, Price, Gross Margin 2015-2020 Table Amgen Inc. Profile Table Amgen Inc. Production, Value, Price, Gross Margin 2015-2020 Table Biogen Idec Profile Table Biogen Idec Production, Value, Price, Gross Margin 2015-2020 Table Novartis AG Profile Table Novartis AG Production, Value, Price, Gross Margin 2015-2020 Table Eli Lilly and Company Profile Table Eli Lilly and Company Production, Value, Price, Gross Margin 2015-2020 Table Johnson and Johnson (Janssen Biotech Inc.) Profile Table Johnson and Johnson (Janssen Biotech Inc.) Production, Value, Price, Gross Margin 2015-2020 Table AbbVie Inc. Profile Table AbbVie Inc. Production, Value, Price, Gross Margin 2015-2020 Figure Global Psoriasis Sales and Growth Rate (2015-2020) Figure Global Psoriasis Revenue ($) and Growth (2015-2020) Table Global Psoriasis Sales by Regions (2015-2020) Table Global Psoriasis Sales Market Share by Regions (2015-2020) Table Global Psoriasis Revenue ($) by Regions (2015-2020) Table Global Psoriasis Revenue Market Share by Regions (2015-2020) Table Global Psoriasis Revenue Market Share by Regions in 2015 Table Global Psoriasis Revenue Market Share by Regions in 2019 Figure North America Psoriasis Sales and Growth Rate (2015-2020) Figure Europe Psoriasis Sales and Growth Rate (2015-2020) Figure Asia-Pacific Psoriasis Sales and Growth Rate (2015-2020) Figure Middle East and Africa Psoriasis Sales and Growth Rate (2015-2020) Figure South America Psoriasis Sales and Growth Rate (2015-2020) Figure North America Psoriasis Revenue ($) and Growth (2015-2020) Table North America Psoriasis Sales by Countries (2015-2020) Table North America Psoriasis Sales Market Share by Countries (2015-2020) Figure North America Psoriasis Sales Market Share by Countries in 2015 Figure North America Psoriasis Sales Market Share by Countries in 2019 Table North America Psoriasis Revenue ($) by Countries (2015-2020) Table North America Psoriasis Revenue Market Share by Countries (2015-2020) Figure North America Psoriasis Revenue Market Share by Countries in 2015 Figure North America Psoriasis Revenue Market Share by Countries in 2019 Figure United States Psoriasis Sales and Growth Rate (2015-2020) Figure Canada Psoriasis Sales and Growth Rate (2015-2020) Figure Mexico Psoriasis Sales and Growth (2015-2020) Figure Europe Psoriasis Revenue ($) Growth (2015-2020) Table Europe Psoriasis Sales by Countries (2015-2020) Table Europe Psoriasis Sales Market Share by Countries (2015-2020) Figure Europe Psoriasis Sales Market Share by Countries in 2015 Figure Europe Psoriasis Sales Market Share by Countries in 2019 Table Europe Psoriasis Revenue ($) by Countries (2015-2020) Table Europe Psoriasis Revenue Market Share by Countries (2015-2020) Figure Europe Psoriasis Revenue Market Share by Countries in 2015 Figure Europe Psoriasis Revenue Market Share by Countries in 2019 Figure Germany Psoriasis Sales and Growth Rate (2015-2020) Figure UK Psoriasis Sales and Growth Rate (2015-2020) Figure France Psoriasis Sales and Growth Rate (2015-2020) Figure Italy Psoriasis Sales and Growth Rate (2015-2020) Figure Spain Psoriasis Sales and Growth Rate (2015-2020) Figure Russia Psoriasis Sales and Growth Rate (2015-2020) Figure Asia-Pacific Psoriasis Revenue ($) and Growth (2015-2020) Table Asia-Pacific Psoriasis Sales by Countries (2015-2020) Table Asia-Pacific Psoriasis Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2015 Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2019 Table Asia-Pacific Psoriasis Revenue ($) by Countries (2015-2020) Table Asia-Pacific Psoriasis Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2015 Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2019 Figure China Psoriasis Sales and Growth Rate (2015-2020) Figure Japan Psoriasis Sales and Growth Rate (2015-2020) Figure South Korea Psoriasis Sales and Growth Rate (2015-2020) Figure Australia Psoriasis Sales and Growth Rate (2015-2020) Figure India Psoriasis Sales and Growth Rate (2015-2020) Figure Southeast Asia Psoriasis Sales and Growth Rate (2015-2020) Figure Middle East and Africa Psoriasis Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Trending Report URLs:

https://crypto-daily.news/uncategorized/473894/covid-19-impact-analysis-global-brows-and-mircoblading-and-lash-extensions-industry-market-research-report-excellent-growth-regions-and-key-players-types-applications-trend-analysis-2026/

Read the original:

Psoriasis Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Global Forecast to 2026 (Based on 2020 COVID-19 Impacts...

Celiac.com 10/06/2020 - One question we get often is about celiac disease and rashes. Specifically, is it common for people with celiac disease to have a rash?

Skin rash alone is not a specific symptom of celiac disease. However, people with celiac disease can have higher rates of certain skin conditions that can cause rashes. Rashes are also not commonly in the top ten complaints of people with celiac disease.

Dermatitis herpetiformis (DH) is a common extraintestinal manifestation of celiac disease, marked by itchy papules and vesicles on the elbows, knees, and buttocks. Dermatitis herpetiformis is a common in people with celiac disease, and is one immediate suspect for anyone with celiac disease who develops a rash.

About 1 out of 8, or about 12 percent of people with celiac disease will also have Dermatitis Herpetiformis (DH). In fact, DH is now regarded as external manifestation of celiac disease in the skin.

It is also possible for people to have DH and not have celiac disease, but everyone with DH should be screened for celiac disease. The good news is that most people with DH see significant improvement on a gluten-free diet. Moreover, patients with refractory DH see major gut improvement on a gluten-free diet.

Some patients with celiac disease have complained of hives, but hives are not common in celiac patients. There have also been studies to show that six out of sixty patients (10%) with Non-Celiac Wheat Sensitivity (NCWS) suffered from contact dermatitis and nickel allergy, double the 5% rate seen in the control group.

Other conditions that can cause skin rashes in celiacs (and non-celiacs) include eczema and psoriasis.

As with DH, a gluten-free diet is becoming a more commontreatment for eczema. People who are gluten intolerant also tend to have more advanced psoriasis. Like eczema, many people with psoriasis improve when patients follow a gluten-free diet.

People with celiac disease have a slightly higher risk of developing shingles (herpes zoster), which could also be triggered by a COVID-19 infection.

Again, a rash all by itself is not a signof celiac disease. However, if you have a rash associated with one of the above conditions AND you have celiac symptoms, such as nausea, vomiting, stomach upset, then you might want to consult a doctor about celiac disease.

See original here:

Is it Common for People with Celiac Disease to Have a Rash? - Celiac Disease and Gluten-Free Diet Support - Celiac.com

PHILADELPHIA, Oct. 6, 2020 /PRNewswire/ --Health Union will lead a live virtual event - the company's first - on Oct. 15 that aims to capture the impact of COVID-19 on people with chronic health conditions and glean insights into how biopharma companies can address changing needs (registration here).

Titled "The COVID-19 Effect: How Pharma Can Adapt to the Evolving Patient Experience," the free event will feature real-time conversations with patient advocates from across Health Union's chronic condition-specific online health communities. Each of the five conversations will focus on how the patient advocates are navigating health-related topics that have taken center stage throughout the coronavirus pandemic, such as telehealth, social distancing and isolation.

These personal conversations between patient advocates and a Health Union team member will be partnered with the company's patient-reported survey data to give attendees an understanding of how these topics will continue to shape the health landscape. Each of these sessions will include advice and "food for thought" on how pharma companies can better address patients' unmet needs related to these topics. Each conversation will be followed by a brief question-and-answer session; attendees can submit questions within the chat function following the session.

The schedule for the virtual event, which runs from 10 a.m. to 3 p.m. ET, is as follows:

"The coronavirus pandemic has impacted everybody in some shape or form, but people living with chronic health conditions have been affected in unique ways that might not be obvious to many," said Tim Armand, co-founder and president of Health Union. "By illuminating these stories during this virtual event - via conversations with our amazing, thoughtful patient advocates - Health Union hopes to inform people who can make a true impact, such as biopharma companies, how they can make a difference."

Interested participants can attend any or all of the sessions throughout the one-day event, and can access the event homepage via web browser or the Cadence app. Register, for free, at eventcadence.com/e/health-union-COVID-effect.

More Information About the Sessions

"MS & Social Distancing: Devin's Resilience" (10-10:30 a.m. ET) will dive into the ups and downs of MultipleSclerosis.net patient advocate Devin Garlit's 20-year journey with multiple sclerosis, including what's changed or stayed the same throughout the pandemic. The conversation will be led by Health Union's Emily Downward, senior director, consumer strategy and storytelling, and Courtney Robertson, executive research director.

During "Psoriasis Used to Isolate Reena, Now it Connects Her" (11-11:30 a.m. ET), PlaquePsoriasis.com patient advocate Reena Ruparelia will discuss her unique experience living with psoriasis, focusing on her relationship with healthcare professionals (HCP) and the positive impact of online connections. The session will be led by Health Union's Lauren Lawhon, chief operating officer, and Katie MacTurk, senior research director.

"Telehealth Perspectives: The Good, The Bad and The Ugly" (noon-12:45 p.m. ET) will feature a roundtable on telehealth experiences, focusing on challenges, opportunities and impact on the HCP-patient relationship. Participants will include ParkinsonsDisease.net advocates Angela Robb and Karl Robb and InflammatoryBowelDisease.net advocate Amanda Osowski. Health Union's Rebecca Braglio, executive director for community development, will lead the conversation.

Migraine.compatient advocate Kerrie Smyres will share what she wishes she knew at the start of her migraine journey, detail her shift to self-care and experiences with telehealth during "Healthcare + Self-Care: Kerrie's Migraine Journey" (1-1:30 p.m. ET). The session will be led by Downward and Robertson.

During "Listen & Learn From People with Lung Cancer, Like Lisa" (2-2:30 p.m. ET), LungCancer.net advocate Lisa Moran will discuss her personal experience living with late-stage lung cancer, focusing on changing treatment during the pandemic and how she copes with isolation and tips for pharma. The conversation will be led by Lawhon and MacTurk.

About Health Union, LLC

Since 2010, Health Union has encouraged social interactions that evolve into valuable online health conversations, helping people with chronic conditions find the information, connection, and validation they seek. The company creates condition-specific online communities publishing original, daily content and continuously cultivating social conversation to support, educate and connect millions of people with challenging, chronic health concerns. Today, the Health Union family of brands includes 29 online health communities, including LungCancer.net, ParkinsonsDisease.net, MultipleSclerosis.net and Migraine.com.

SOURCE Health Union

Home

Here is the original post:

Health Union Virtual Event to Share Patient Perspectives from COVID-19, How It Will Shape Health Landscape - PRNewswire

CBD (cannabidiol) is everywhere these days. From topical salves, lotions, oils, to a variety of foods and drinks. While we typically hear about all of the wonderful ways CBD works for pain relief and anxiety, it has also made its way into the skincare industry. So how can something like CBD be beneficial for our skin?

Our body produces a type of cannabinoid, known as endocannabinoids, which support the endocannabinoid system (ECS). This system regulates the immune system functions, inflammatory response, and so much more. When our ECS is deficient, CBD oil can penetrate the skin and help support that system by imitating endocannabinoids. In other words, CBD helps restore a homeostatic balance to an out-of-whack ECS. Pain, inflammation, and an imbalance in skin cells, sebum glands, and the immune system are some of the root causes of many skin issues so adding CBD to your skincare regimen makes total sense. Here are just a few issues CBD oil can help with.

CBD oil contains Omega-3 and Omega-6 fatty acids, which helps stimulate the production of collagen and prevents excessive water loss. Increased collagen production and hydration help to prevent the signs of aging caused by free radicals, such as reddened skin tone, dullness, fine lines, and wrinkles, for more youthful skin.

Psoriasis, an autoimmune disease, causes the body to attack healthy skin cells and speed up their life cycle. Cells multiply quickly, leading to scaly red spots. Psoriasis can be painful and hard to control for those who suffer with the disease. CBD helps relieve pain and inflammation while decreasing the rapid skin cell multiplication by working with our bodys natural endocannabinoid system to restore balance to pain, inflammation, and immune responses.

CBD oil acts as a balancer in instances of acne and dry skin with its antibacterial properties and sebum oil regulation. It regulates over-producing acne-causing sebum oil production, which helps to keep the skin free of excess bacteria that leads to clogged pores. In dry skin, it regulates the sebaceous glands to encourage oil production. This makes CBD oil a great choice for sensitive skin, as well as combination skin types. CBDs anti-inflammatory and antioxidant properties alleviate inflammation from irritated skin and help speed up healing time as well.

Eczema causes patches of skin to turn red, crack, and become itchy and inflamed. Since CBD has a strong relation to the bodys natural endocannabinoid system, which directly relates to the allergic inflammation believed to be the leading cause of eczema, this makes CBD oil an excellent option to alleviate pain and inflammation. CBD also helps to relieve the dry skin caused by eczema.

Hempfield Botanicals has you covered with these high-quality CBD products that could have you seeing major improvement within two weeks:

Fortify Face Oil defies the effects of aging and nourishes dry skin with a vitamin-C rich CBD oil blend. Made with soothing borage seed oil, hydrating hemp seed oil, and other specially selected oils, Fortify fights free radicals and rejuvenates skin. Fortify is also an LNE & SPAs Best Product Winner of 2020.

Soothe Face Oil calms sensitive and acne-prone skin with its anti-inflammatory CBD oil blend. Made with healing borage seed oil, nourishing hemp seed oil, and other specially selected oils, Soothe hydrates temperamental skin without clogging pores. Soothe is a 2020 Beauty Awards Winner for Organic Spa Magazine.

When shopping for CBD skincare products, there are many low-quality ones out there, so make sure you do your research. Hempfield Botanicals is a Certified B Corporation, meeting higher standards of social and environmental performance, transparency, and

accountability. Their formulations contain organically-grown whole-plant hemp CBD extracts sourced from sustainable farms in Pennsylvania. Every batch is triple tested for potency, quality, and purity to ensure consistent,effective products every time. If quality and effectiveness is what you are looking for, Hempfield Botanicals should be your go-to brand.

For more information aboutHempfield Botanicals,please visithttps://hempfieldbotanicals.com/

Originally posted here:

Here are some CBD products to add to your skin care routine - LancasterOnline

FDA Approves Golimumab for Active Polyarticular Juvenile Idiopathic Arthritis, Extension of PsA Indication

Golimumab is a fully human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody designed to target soluble and transmembrane bioactive forms of human TNF-alpha. When overproduced in the body, TNF-alpha is a protein that can cause chronic inflammation.

"This latest FDA approval of Simponi Aria for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment," said Mathai Mammen, MD, PhD, global head of Janssen Research and Development at Johnson & Johnson, in a press release. "For more than 20 years, we at Janssen have been committed to researching anti-TNF biologic agents for immune-mediated diseases and are encouraged to expand treatment options for these patients."

Characterized by symptoms of arthritis that persist for 6 weeks or more before the age of 16 years, JIA is a group of disorders that affects 300,000 children in the United States. The form of JIA that is most common is polyarticular, which is characterized by inflammation in more than 4 joints, resembling adult rheumatoid arthritis (RA).

Among pediatric patients, PsA is one of the rarest subtypes of JIA. PsA results in symptoms that are similar in both children and adults, which include joint inflammation and skin lesions that are commonly associated with psoriasis.

"For far too long, children with pJIA or PsA have had limited treatment options," said Seth D. Ginsberg, co-founder and president of the Global Healthy Living Foundation and CreakyJoints, in a press release. "This approval represents an important step forward for these children and their families."

The approval for golimumab was based on results from the GO-VIVA phase 3 clinical trial. The open-label study included children aged 2 to 17 years with JIA with active polyarthritis who had active arthritis in 5 or more joints. All patients included in the trial had also received a treatment with methotrexate for at least 2 months prior to treatment with golimumab.

The researchers found that the pharmacokinetic exposure of golimumab in the GO-VIVA clinical trial was consistent with the results of 2 other phase 3 clinical trials assessing golimumab in adult patients with moderately to severely active RA and active PsA.

The results also demonstrated that the efficacy of golimumab was consistent with the responses of adult patients with RA. Additionally, the adverse effects were consistent with the previously established safety profile of golimumab in adult patients with RA and PsA.

"Due to the limited availability of pediatric patients for inclusion in clinical trials, it can be challenging to build clinical studies for this young patient population," said Daniel J. Lovell, the Joseph E. Levinson professor of pediatric rheumatology at Cincinnati Children's Hospital MedicalCenter, in a press release. "Given these challenges, I am pleased to see Janssen advance the approval of a new treatment option for pediatric patients with pJIA and PsAan important milestone in the treatment of these complex, heterogeneous diseases."

REFERENCESIMPONI ARIA (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older. Horsham, PA: Janssen Pharmaceutical Companies; September 30, 2020. prnewswire.com/news-releases/simponi-aria-golimumab-approved-by-the-us-food-and-drug-administration-for-active-polyarticular-juvenile-idiopathic-arthritis-and-extension-of-its-active-psoriatic-arthritis-indication-in-patients-2-years-of-age-and-older-301141976.html?tc=eml_cleartime. Accessed October 1, 2020.

View original post here:

FDA Approves Golimumab for Active Polyarticular Juvenile Idiopathic Arthritis, Extension of PsA Indication - Pharmacy Times

People with psoriasis who are on biologic therapies may get an added boost to their overall health: a reduced risk of heart disease.

According to a study published in the September 2020 issue of the journal Circulation: Cardiovascular Imaging, people who received biologics like adalimumab and ustekinumab for one year to manage their psoriasis had lower levels of a type of coronary plaque called lipid-rich necrotic core (LRNC) compared with people who didnt receive the drugs.

LRNC has been linked with higher risk of heart attack and stroke in people with coronary artery disease.

The Centers for Disease Control and Prevention (CDC) describes plaque as cholesterol deposits that accumulate on the walls of arteries, causing blockages that can lead to coronary artery disease. Coronary artery disease is the most common form of heart disease in the United States, affecting an estimated 18 million people, the CDC says.

[Our] current hypothesis is that treatment of psoriasis may result in a lowering of the risk of cardiovascular disease over time, explains Joel M. Gelfand, MD, director of the Psoriasis and Phototherapy Treatment Center at University of Pennsylvanias Perelman School of Medicine Philadelphia, who was one of the coauthors of the new study.

RELATED: The Consumers Guide to Biologics for Psoriasis

It seems biologic therapy as well as phototherapy two commonly used treatments for psoriasis may both work to reduce levels of LRNC in the blood. LRNC is among several leading biomarkers (measurable signs) that can predict future heart attacks, Dr. Gelfand says.

Biologics, which target specific areas of the immune system, have been used for psoriasis treatment since the early 2000s. The biologics used to treat psoriatic disease block the action of a specific type of immune cell a T cell or proteins in the immune system, such as tumor necrosis factor-alpha (TNF-alpha), interleukin 17-A, or interleukins 12 and 23, according to the National Psoriasis Foundation.

TNF-alpha and the interleukins all play a major role in psoriasis and psoriatic arthritis.

RELATED: 7 Signs You May Need to Change Your Psoriasis Treatment

For the new study, Gelfand and his colleagues enrolled 209 people with psoriasis who had not yet been treated with biologics. Roughly one-half were prescribed biologic therapies to treat their condition, while the rest were not.

LRNC for people in both groups was assessed using coronary computed tomography angiography, with measurements taken at the beginning of the study and, again, one year later.

On average, those who received biologic therapy saw their LRNC decline from 3.12 square millimeters (mm2) to 2.97 mm2 or about 5 percent. Conversely, those who werent on biologic therapy saw LRNC increase from 3.12 to 3.34 mm2, on average a 6 percent rise.

RELATED: 8 Health Conditions Linked to Psoriasis

Although larger studies are needed to confirm the positive effects of biologics on LRNC and heart disease risk, the findings are exciting, Gelfand says, because recent research suggeststhat people with psoriasis are at increased risk for heart disease.

And this risk is more clinically significant in those with more severe skin disease, Gelfand notes. People with psoriasis should be screened for traditional cardiovascular risk factors such as high blood pressure, diabetes, and high cholesterol, and they should adopt a heart-healthy lifestyle whether theyre on biologics or not.

RELATED: Psoriasis and Heart Disease: The Hidden Connection

Go here to read the rest:

Psoriasis Biologics and Heart Disease Risk - Everyday Health

By: Lifestyle Desk | New Delhi | Updated: September 22, 2020 10:39:01 pmThe lesions usually occur on cooler places of the skin like the elbows, the knees, the scalp, on the palms, soles, etc. (Source: Pixabay)

The body reacts differently to the changing weather, and those who suffer from skin conditions would know that weather always factors in whenever there is a sudden deterioration of the condition.

Eczema (or dermatitis) is a condition wherein the patient develops severely-itchy lesions with fluid-filled vesicles/oozing during an acute exacerbation phase, and psoriasis is a skin disease wherein the turnover of the skin speeds up. Instead of the average two months, the skin turns over in three or four days, leading to red or pink lesions with silvery-white scaling. The lesions usually occur on cooler places of the skin like the elbows, the knees, the scalp, on the palms, soles, etc.

Dr Smriti Naswa Singh, Consultant Dermatologist, Fortis Hospital, Mulund, says the reason for developing eczema could be external (sun, aero-allergens, some irritant applications, etc.) or internal (familial allergic tendency, endogenous eczema, old age, or a manifestation of other internal diseases like diabetes, chronic liver or kidney disease, cancer, HIV, etc.). While psoriasis and eczema do not spread to others, they do flare up during winters or cooler seasons, since the dryness of the skin increases, leading to more itchiness; when a person scratches, the patches aggravate.

ALSO READ |Home-based care for COVID-19 infection; here are some dos and donts

Dr Singh suggest the following ways to control the outbursts:

* Change of weather to cooler weather makes the skin dry. Applying a moisturizer is key. Moisturizers work best on wet skin and have to be frequently applied throughout the day.

* Itch-scratch is a vicious cycle that needs to be broken to control the exacerbation. So whenever one feels itchy, they should apply moisturizer and not scratch the area. Oral and topical medications help in controlling the itching sensation; do consult a dermatologist for guidance.

* Weather-change is usually associated with an increase in aero-allergens, so those suffering from atopic dermatitis (eczema due to allergic tendency running in family) suffer more. They should try to keep their immunity high by consuming fruits and vegetables, taking adequate rest and staying away from common allergens like dust, sweat, synthetic clothes, wool etc. Cotton clothing is the preferred choice.

* Stress is known to exacerbate both psoriasis and eczema, and hence, should be avoided. Adequate rest and work-life balance are important factors.

ALSO READ |What patients on dialysis need to know about controlling diabetes

* Psoriasis is directly linked to metabolic syndrome. Psoriatic patients have a tendency to be more prone to lifestyle diseases like diabetes, hypertension and altered lipid profile. If the person indulges in oily foods, junk foods, gains weight, does not exercise, psoriasis can worsen. Adopting appropriate lifestyle measures will help in such scenarios.

* During the COVID-19 pandemic, people have been overzealous in washing hands and using hand sanitizers. Detergent strips off the skin from natural moisturizing factors for at least 6 hours before the skin replenishes it. Sanitizers can be irritant/allergic to sensitive skin. Refrain from excessive use of soaps/washing detergents/sanitizers. Applying a moisturizer after washing/cleaning your hands/feet will help prevent the aggravation.

A patient can prevent exacerbation of psoriasis and eczema by keeping in mind the aforementioned methods. But for treatment of the lesions, one needs a carefully-formulated, tailor-made prescription of oral/systemic and topical medications. You should visit your dermatologist at first instance of the flare-up, or when the rashes are noted; these can be treated with topical cream formulations alone.

ALSO READ |How do COVID-19 triggered blood clots affect the heart? A doctor answers

If unfortunately, there is delay and the disease becomes extensive, oral medications may be required and sometimes, especially in psoriasis and certain cases of endogenous eczemas, there may be a need for control of acute exacerbation. We call such cases as acute skin failure with risk of hypovolemia, infection, electrolyte imbalance and thermal dysregulation, Dr Singh explains.

For more lifestyle news, follow us: Twitter:lifestyle_ie|Facebook:IE Lifestyle| Instagram:ie_lifestyle

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

Visit link:

Heres how you can control eczema and psoriasis flare-up during changing weather - The Indian Express

A third of patients with the skin condition psoriasis develop psoriatic arthritis, for which are some treatments but no cure.

The long-term condition, which causes affected joints to become swollen, stiff and painful, can worsen over time. In the worst cases, it can permanently damage joints, meaning surgery is required.

But there was new hope for those with the condition on Monday, when a study was published showing psoriatic arthritis may be activated by the same trigger in different patients.

The research by the Wellcome Sanger Institute and University of Oxford gives the strongest evidence yet of a single cause for the disease after identifying high levels of a specific receptor in immune cells from patients.

It could help scientists find the exact molecular trigger, which would raise hopes of finding a targeted treatment.

The researchers used single cell technology and machine learning to analyse thousands of individual immune cells from fluid drained from the knees of patients with psoriatic arthritis.

Dr Hussein Al-Mossawi, honorary research associate at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) at the University of Oxford, said: Our data suggest that psoriatic arthritis doesnt just appear out of nowhere. Each receptor is like a unique lock that recognises a molecular key and we discovered, that across the patients, they are recognising a common molecule.

This gives the first evidence that the T cells are seeing and reacting to the same molecule, which acts as a trigger for the disease. We dont know the exact culprit yet, but this is a great step forward in understanding the disease.

Dr Sam Behjati, group leader and Wellcome Trust intermediate clinical fellow at the Wellcome Sanger Institute , said: Our study produced the largest single cell dataset from psoriatic arthritis patients to date.

It is helping us to understand the intricate mechanisms behind psoriatic arthritis, including starting to unravel the signals that tell the T cells to cross over into the joint fluid.Imagine the cells as train passengerswith a ticket that tells them at which station to get off - the single cell data is allowing us to read that destination for each cell, and understand the signals.

Paul Bowness, professor of experimental rheumatology at NDORMS said: Our findings indicate that specific T cells are likely to be targeted to enter the joint, where they are triggered to expand, creating inflammation and causing psoriatic arthritis.

The next stage of research will be to find the key that is unlocking the disease in patients - from the signals that direct cells to the joint, to what then triggers them to expand. If we can understand these, we could move towards creating therapies that would prevent this, potentially providing a cure.

Read more

Cancer immunotherapy boost as Sanger Institute and University of Cambridge reveal role of immune cell steroids

Fresh hope of new cancer and autoimmune disease therapies as Wellcome Sanger Institute creates map of thymus gland

Babraham Institute and Sanger scientists find dark matter switch is key to inflammatory diseases

See the original post:

Hopes of breakthrough for psoriatic arthritis patients after Sanger Institute and Oxford University discovery - Cambridge Independent

Among patients with psoriatic arthritis (PsA), ixekizumab may be superior to adalimumab in terms of joint and skin improvement, according to study results published in Annals of the Rheumatic Diseases.

Results of the SPIRIT head-to-head trial indicated that ixekizumab was superior to adalimumab with regard to the achievement of the American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 responses at 24 weeks..

The 52-week, multicenter, phase 3b/4, open-label, randomized, blinded-assessor study (ClinicalTrials.gov Identifier: NCT03151551) aimed to investigate the efficacy and safety of ixekizumab compared with adalimumab in adults with PsA. Patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and no previous exposure to biologic DMARDs were randomly assigned 1:1 to receive either ixekizumab or adalimumab. The primary outcome was superiority of ixekizumab to adalimumab according to ACR50 and PASI100 responses after 24 weeks. Prespecified outcomes after 52 weeks included musculoskeletal, psoriasis, quality of life outcomes, and safety.

The study cohort included 566 patients, of whom 283 received ixekizumab and 283 received adalimumab. Of the total cohort, 246 participants (87%) who received ixekizumab and 237 (84%) who received adalimumab completed the 52-week study visit.

At week 52, treatment with ixekizumab vs adalimumab was associated with a higher percentage of patients achieving both ACR50 and PASI100 (39.2% vs 26.1%, respectively; P <.001). Differences between the groups were evident after 8 weeks, and maintained throughout the study. A significantly higher percentage of patients who received ixekizumab achieved PASI100 (64.3% vs 41.3%, respectively; P .001). However, similar response rates for ACR50, ACR20, and ACR70 were observed with ixekizumab and adalimumab, as were other efficacy outcomes, including treat-to-target outcomes, enthesitis, and dactylitis resolution.

When used as monotherapy for 52 weeks, ixekizumab was superior to adalimumab for simultaneous achievement of ACR50 and PASI100 (38% vs 19%, respectively; P =.007), and PASI100 responses (66% vs 35%, respectively; P <.001). While response rates were higher with a combination of adalimumab and conventional synthetic DMARDs vs adalimumab monotherapy, response rates for ixekizumab were consistent irrespective of concomitant conventional synthetic DMARD use.

There were no new safety findings for either ixekizumab or adalimumab.

The study had several limitations, including the open-label design, potential assessment bias, and no available data on antidrug antibodies to ixekizumab or adalimumab.

SPIRIT-H2H study comparing ixekizumab [vs] adalimumab is the first fully disclosed direct head-to-head study in PsA; its findings over 52 weeks will inform future treatment recommendations and may impact selection of therapy in bionaive patients with active PsA, the researchers concluded.

Disclosure: This clinical trial was supported by Eli Lilly and Company. Please see the original reference for a full list of authors disclosures.

Reference

Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis nave to biological disease-modifying antirheumatic drug: final results by week 52. Published online July 13, 2020. Ann Rheum Dis. doi:10.1136/annrheumdis-2020-217372

Read more:

Greater Joint and Skin Improvement With Ixekizumab vs Adalimumab in Patients With Psoriatic Arthritis - Rheumatology Advisor

Fort Collins, Colorado Reports Globe recently added the Psoriasis Treatment Market Research Report that provides a thorough investigation of the market scenario of the market size, share, demand, growth, trends, and forecast from 2020-2027. The report covers the impact analysis of the COVID-19 pandemic. COVID-19 pandemic has affected the export-import, demands, and trends of the industry and is expected to have some economic impact on the market. The report provides a comprehensive analysis of the impact of the pandemic on the overall industry and offers insights into a post-COVID-19 market scenario.

The report primarily mentions definitions, classifications, applications, and market overview of the Psoriasis Treatment industry. It also covers product portfolios, manufacturing processes, cost analysis, structures, and gross margin of the industry. It also provides a comprehensive analysis of the key competitors and their regional spread and market size.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=65209

Competitive Analysis:

The report provides a comprehensive analysis of the companies operating in the Psoriasis Treatment market, along with their overview, business plans, strengths, and weaknesses to provide a substantial analysis of the growth through the forecast period. The evaluation provides a competitive edge and understanding of their market position and strategies undertaken by them to gain a substantial market size in the global market.

Key features of the Report:

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=65209

Additionally, the report is furnished by the advanced analytical data from SWOT analysis, Porters Five Forces Analysis, Feasibility Analysis, and Investment Return Analysis. The report also provides a detailed analysis of the mergers, consolidations, acquisitions, partnerships, and government deals. Along with this, an in-depth analysis of current and emerging trends, opportunities, threats, limitations, entry-level barriers, restraints and drivers, and estimated market growth throughout the forecast period are offered in the report.

Market Breakdown:

The market breakdown provides market segmentation data based on the availability of the data and information. The market is segmented on the basis of types and applications.

Psoriasis Treatment Market Segmentation, By Type

Psoriasis Treatment Market Segmentation, By Applications

Request customization of the report @https://reportsglobe.com/need-customization/?rid=65209

The report provides additional analysis about the key geographical segments of the Psoriasis Treatment Market and provides analysis about their current and previous share. Current and emerging trends, challenges, opportunities, and other influencing factors are presented in the report.

Regional analysis includes an in-depth study of the key geographical regions to gain a better understanding of the market and provide an accurate analysis. The regional analysis coversNorth America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.

Objectives of the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-psoriasis-treatment-assessment/

Thank you for reading our report. To learn more about report details or for customization information, please contact us. Our team will ensure that the report is customized according to your requirements.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Read the rest here:

Psoriasis Treatment Market Size, Analytical Overview, Key Players, Growth Factors, Demand, Trends And Forecast to 2027 - The Daily Chronicle